Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA225180
Max Phase: Preclinical
Molecular Formula: C19H19N5O6S
Molecular Weight: 445.46
Molecule Type: Small molecule
Associated Items:
ID: ALA225180
Max Phase: Preclinical
Molecular Formula: C19H19N5O6S
Molecular Weight: 445.46
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: Cc1[nH]c2nc(N)[nH]c(=O)c2c1Sc1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1
Standard InChI: InChI=1S/C19H19N5O6S/c1-8-14(13-15(21-8)23-19(20)24-17(13)28)31-10-4-2-9(3-5-10)16(27)22-11(18(29)30)6-7-12(25)26/h2-5,11H,6-7H2,1H3,(H,22,27)(H,25,26)(H,29,30)(H4,20,21,23,24,28)/t11-/m0/s1
Standard InChI Key: DSIACOJIIGFHHZ-NSHDSACASA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 445.46 | Molecular Weight (Monoisotopic): 445.1056 | AlogP: 1.34 | #Rotatable Bonds: 8 |
Polar Surface Area: 191.26 | Molecular Species: ACID | HBA: 7 | HBD: 6 |
#RO5 Violations: 1 | HBA (Lipinski): 11 | HBD (Lipinski): 7 | #RO5 Violations (Lipinski): 2 |
CX Acidic pKa: 3.05 | CX Basic pKa: 2.58 | CX LogP: 0.35 | CX LogD: -5.87 |
Aromatic Rings: 3 | Heavy Atoms: 31 | QED Weighted: 0.30 | Np Likeness Score: -0.42 |
1. Gangjee A, Jain HD, Phan J, Lin X, Song X, McGuire JJ, Kisliuk RL.. (2006) Dual inhibitors of thymidylate synthase and dihydrofolate reductase as antitumor agents: design, synthesis, and biological evaluation of classical and nonclassical pyrrolo[2,3-d]pyrimidine antifolates(1)., 49 (3): [PMID:16451071] [10.1021/jm058276a] |
2. Gangjee A, Jain HD, McGuire JJ, Kisliuk RL.. (2004) Benzoyl ring halogenated classical 2-amino-6-methyl-3,4-dihydro-4-oxo-5-substituted thiobenzoyl-7H-pyrrolo[2,3-d]pyrimidine antifolates as inhibitors of thymidylate synthase and as antitumor agents., 47 (27): [PMID:15615522] [10.1021/jm040144e] |
3. Gangjee A, Li W, Yang J, Kisliuk RL.. (2008) Design, synthesis, and biological evaluation of classical and nonclassical 2-amino-4-oxo-5-substituted-6-methylpyrrolo[3,2-d]pyrimidines as dual thymidylate synthase and dihydrofolate reductase inhibitors., 51 (1): [PMID:18072727] [10.1021/jm701052u] |
4. Gangjee A, Qiu Y, Li W, Kisliuk RL.. (2008) Potent dual thymidylate synthase and dihydrofolate reductase inhibitors: classical and nonclassical 2-amino-4-oxo-5-arylthio-substituted-6-methylthieno[2,3-d]pyrimidine antifolates., 51 (18): [PMID:18800768] [10.1021/jm8006933] |
5. Zhang X, Zhou X, Kisliuk RL, Piraino J, Cody V, Gangjee A.. (2011) Design, synthesis, biological evaluation and X-ray crystal structure of novel classical 6,5,6-tricyclic benzo[4,5]thieno[2,3-d]pyrimidines as dual thymidylate synthase and dihydrofolate reductase inhibitors., 19 (11): [PMID:21550809] [10.1016/j.bmc.2011.03.067] |
Source(1):